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Background: COPDPredict™ is a novel digital application dedicated to providing early 
warning of imminent COPD (chronic obstructive pulmonary disease) exacerbations for 
prompt intervention. Exacerbation prediction algorithms are based on a decision tree 
model constructed from percentage thresholds for disease state changes in patient-reported 
wellbeing, forced expiratory volume in one second (FEV1) and C-reactive protein (CRP) 
levels. Our study determined the validity of COPDPredict™ to identify exacerbations and 
provide timely notifications to patients and clinicians compared to clinician-defined episodes.
Methods: In a 6-month prospective observational study, 90 patients with COPD and frequent 
exacerbations registered wellbeing self-assessments daily using COPDPredict™ App and mea-
sured FEV1 using connected spirometers. CRP was measured using finger-prick testing.
Results: Wellbeing self-assessment submissions showed 98% compliance. Ten patients did 
not experience exacerbations and treatment was unchanged. A total of 112 clinician-defined 
exacerbations were identified in the remaining 80 patients: 52 experienced 1 exacerbation; 28 
had 2.2±0.4 episodes. Sixty-two patients self-managed using prescribed rescue medication. 
In 14 patients, exacerbations were more severe but responded to timely escalated treatment at 
home. Four patients attended the emergency room; with 2 hospitalised for <72 hours. 
Compared to the 6 months pre-COPDPredict™, hospitalisations were reduced by 98% (90 
vs 2, p<0.001). COPDPredict™ identified COPD-related exacerbations at 7, 3 days (median, 
IQR) prior to clinician-defined episodes, sending appropriate alerts to patients and clinicians. 
Cross-tabulation demonstrated sensitivity of 97.9% (95% CI 95.7–99.2), specificity of 84.0% 
(95% CI 82.6–85.3), positive and negative predictive value of 38.4% (95% CI 36.4–40.4) 
and 99.8% (95% CI 99.5–99.9), respectively.
Conclusion: High sensitivity indicates that if there is an exacerbation, COPDPredict™ informs 
patients and clinicians accurately. The high negative predictive value implies that when an 
exacerbation is not indicated by COPDPredict™, risk of an exacerbation is low. Thus, 
COPDPredict™ provides safe, personalised, preventative care for patients with COPD.
Keywords: COPD acute events, preventative care, digital enabled-healthcare, automated 
health-status algorithms, diagnostic accuracy, reduced hospitalisations
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung condition 
characterized by persistent respiratory symptoms and life-changing disruptive 
exacerbations associated with a faster decline in lung function, poorer quality of 
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life and increased mortality.1,2 Over 70% of patients living 
with COPD experience exacerbations within 3 years of 
diagnosis;3,4 and up to 47% may have two or more exacer-
bations a year irrespective of airflow severity (so-called 
‘frequent exacerbator phenotype’).5,6 Exacerbations of 
COPD have a global detrimental and substantial impact 
on patients, healthcare resources and the wider society. 
Exacerbations prevent many working-age individuals 
from working, with billions of dollars lost through reduced 
productivity.7 Severe exacerbations remain the 2nd com-
monest cause of emergency hospital admissions; with 1 in 
3 patients readmitted within 3 months of discharge.8,9 
These hospitalisations account for around two-thirds of 
all COPD-related healthcare costs.10 Frequent moderate 
episodes are community-treated but still consume signifi-
cant primary care resources.11 The COVID-19 pandemic- 
induced changes in healthcare provision, amidst ‘lock-
down’ restrictions and reduced specialist access, have 
increasingly shifted service provision and treatment costs 
of COPD exacerbations onto community care resources.12
Changes in dyspnoea, coughing and/or sputum produc-
tion often precede COPD exacerbations. As symptoms 
vary within the same day and/or daily, patients cannot 
easily judge the significance of such changes and so fail 
to follow physician-recommended ‘action plans’ and 
respond promptly to exacerbations.13,14 Reports show 
that patients do not adhere to their provided action plans 
in about 50% of exacerbations.15
Clearly COVID-19 is mandating the transformation of 
healthcare delivery for chronic disease management such 
as COPD, with technological advances making it possible 
for clinicians to monitor patients remotely and safely at 
home and guide appropriate treatment.16 Developing 
models of care based around prevention through 
a combination of remote monitoring and personalised 
exacerbation prediction could optimize action plans and 
tailor exacerbation management, reducing overall service 
delivery costs. This approach would crucially address 
patients’ needs for prompt access to specialist care and 
appropriate treatment as required. When exacerbations are 
treated promptly, exacerbation severity, recovery time and 
hospital admissions/readmissions can be reduced.17 
Indeed, there is a time window between the initial exacer-
bation symptoms/signs and subsequent hospitalisation 
within which there is an opportunity for preventative 
intervention.18–20
COPDPredict™ is a customized digital health applica-
tion collaboratively designed and developed by clinicians 
and an “experts by experience” patient group to assist 
patient self-management of their condition. This collabora-
tive design approach facilitated an appreciation of what 
was important to patients in experiencing exacerbations 
and thereof, the inclusion of elements to enable them to 
identify COPD-related exacerbations early, enabling 
prompt intervention. COPDPredict™ allows patients to 
collect patient-reported outcomes and bio-physiological 
data via an App and connected devices (eg, smart spirom-
eters) and share information securely with their healthcare 
team. Clinicians can review all patients’ health data in real 
time using a bespoke decision support dashboard. As there 
is marked heterogeneity amongst COPD populations, 
COPDPredict™ is programmed to automatically establish 
patient-specific critical baseline bio-clinical profiles so that 
prediction of exacerbation is personalised and clinically 
meaningful. Indeed, an individualised profile of relevant 
health indicators which could be tracked over time was 
identified as important by patients to aid their self- 
management, thus avoiding the conventional one-size-fits- 
all approach with static thresholds21 or subjective setting 
of per patient reference values by healthcare teams.22 
A systematic review of clinical prediction models for 
COPD exacerbations observed that when predictor avail-
ability and practical applicability were considered, none of 
the models evaluated at that stage were deemed ready for 
clinical implementation.23 With COPDPredict™, patient 
health data is continuously processed using proprietary 
cloud-based algorithms, with the driving algorithm deci-
sion tree constructed from percentage thresholds for dis-
ease state changes in patient-reported wellbeing, forced 
expiratory volume in one second (FEV1) and blood- 
based C-reactive protein (CRP) levels.24,25 Accordingly, 
COPDPredict™ aims to 1) determine an individual’s 
COPD health status in real time, 2) predict imminent 
exacerbations in an early phase, and 3) provide early 
warning alerts directly to both patients and clinicians for 
prompt and adequate action to prevent clinical deteriora-
tion and unnecessary hospitalisations.
In this study, we evaluated whether COPDPredict™ can 
be safely used by patients with COPD and their clinical 
teams in the everyday management of COPD. More speci-
fically, we determined the sensitivity and specificity of the 
prediction algorithm to differentiate between the varying 
health phases of patients with COPD, identifying imminent 
exacerbations and providing their timely notification to both 
patients and clinicians for appropriate intervention.
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Materials and Methods
Study Design, Population and Sample Size
We performed a 6-month prospective observational study in 
a North Midlands community-setting (UK) involving 90 
patients with COPD between May 2017 and April 2018. 
Individuals were identified and randomly selected, indepen-
dent of severity, from the University Hospitals of North 
Midlands NHS Trust research and outpatient clinic databases 
(Figure 1). Inclusion criteria included (i) established COPD 
confirmed by spirometry and categorized according to 
GOLD guidelines;26 (ii) history of frequent exacerbations 
with two or more documented acute episodes27 and 
a minimum of one COPD-related hospitalisation in the pre-
ceding 6 months; (iii) clinically stable and exacerbation-free 
in the six weeks prior to enrolment. Individuals with other 
respiratory disorders and unstable co-morbidities, an inability 
to consent and/or inability/unwilling to use COPDPredict™ 
were excluded. Patients were enrolled using staggered entry 
points and remained on the study for a maximum of 6 
months. Staggered entry enabled the research team to man-
age effective set-up of COPDPredict™ in the patients’ 
homes and ensure clear patient understanding of the required 
data entry. All recruited patients were required to have inter-
net access. However, all patients were given mobile tablets 
(Galaxy A3 Samsung®, South Korea) pre-installed with the 
COPDPredict™ application (App).
Longitudinal recording of bio-clinical metrics in the 
study cohort allowed stable to prodromal to exacerbation 
phases to be determined. Within subject differences could 
be generated and summarised with appropriate 95% 
confidence intervals; a previous study24 indicated that 
a minimum sample of 40 COPD patients would be suffi-
cient. Therefore, we concluded that a total sample of 90 
patients with COPD and frequent exacerbator phenotype 
would provide reasonable estimates of population differ-
ences and standard deviation across the different disease 
phase dynamics as well as enough exacerbations for cross- 
validation of the prediction algorithm.
The study was conducted in accordance with the 
Declaration of Helsinki. Ethical approval was granted for 
the study from the North West - Greater Manchester South 
(12/NW/0623) and Central Research Ethics Committees 
(15/NW/0638); UK CPMS ID 19566. All patients were 
provided with a Participant Information Sheet. All patients 
gave informed written consent to participate and were 
given no reimbursement.
Data Collection Protocol
All 90 patients used the COPDPredict™ App and 
a provided BT smart lung monitor (Vitalograph®, 
Ireland) to self-monitor their COPD in their homes. 
Wellbeing self-assessment was based on a set of questions 
and a choice of answers from which a person could choose 
how they felt (Figure 2A and B); with responses set out 
simply using a five-level Likert scale (please see 
Supplementary Information). An overall wellbeing score 
was automatically calculated by the App from the answers 
supplied to 5 key scored components in the self- 
assessment relating to breathing, cough, sputum and activ-
ities of daily living.24 The Bluetooth-enabled spirometer 
Figure 1 Study flowchart total number of patients screened and included/excluded for the study. This image is the property of the author.
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allowed patients to perform lung function at home and the 
result automatically captured into the App. Blood CRP 
levels were measured by the research team using finger- 
prick testing (Eurolyser Diagnostica®, Austria), with 
results inputted into the App. Induction was carried out 
in the patient’s home: Each patient was given an initial 
face-to-face coaching session by the research team on how 
to use COPDPredict™. Further support was provided 
throughout the study for any problems or concerns 
regarding use of the technology; patients could also con-
tact the team via the secure within-App messaging facility.
Critical baseline data on wellbeing, physiological 
(FEV1) and biomarker (CRP) parameters were established 
for each patient in the first fortnight post-enrolment. 
Thereafter, for the remaining study period, patients per-
formed their wellbeing assessment daily and spirometry 
weekly. The only derogation to this protocol was during 
algorithm-prompted notifications of a change in health 
Figure 2 (A) Screenshot of the COPDPredict™ Wellbeing self-assessment opening screen. (B) Screenshot of the first page of the Wellbeing self-assessment Both images 
are the property of the author.
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status and/or clinical team instruction for additional well-
being self-assessment, FEV1 and/or CRP tests.
Patients could provide any additional information 
about their health that they thought appropriate in 
a dedicated free text section. All patients were provided 
with “standard rescue” medication of a 5-day course of 
oral steroids (prednisolone 30mg/day) and antibiotics such 
as doxycycline, amoxicillin, clarithromycin [the antibiotic 
and dose used was determined by the individual’s previous 
treatment history], allowing them to self-manage COPD 
exacerbations in line with their clinician-prescribed action 
plans.28,29 Patients were advised the clinical team would 
remotely monitor COPDPredict™ usage and data entry 
daily, and would be contacted by clinicians as appropriate.
The clinical team monitored patients’ progress using 
a web-based decision support dashboard. Exacerbation 
alerts produced by the prediction algorithm were sent in 
real time to both patients and clinicians; patients were also 
directed to self-management action plans. Treatment plan 
changes could also be activated by clinicians based on 
their judgement at the time either via text/telephone mes-
sage or by nurse-led home visits as appropriate. The clin-
ical team consisted of 2 respiratory physicians and 2 
respiratory-trained specialist nurses.
Definition of COPD Exacerbations
Both patient-based and clinician-based definitions were 
used to compare with the COPDPredict™-driven exacer-
bation alerts.
Current guidelines were used for defining COPD 
exacerbations as acute events characterized by 
a worsening of the patient’s respiratory symptoms that 
were beyond normal day-to-day variations and leading to 
changes in medication.30 A mild/moderate exacerbation 
was defined as an increase in respiratory symptoms for 
two consecutive days or more, with at least two major 
symptoms (dyspnoea, sputum purulence, sputum volume) 
or a major plus a minor symptom (wheeze, cold, sore 
throat, cough)31 and requiring a change in usual treatment 
with introduction of systemic steroids and/or antibiotics by 
the decision of a clinician; a severe exacerbation was an 
episode that also required hospitalisation. Defining exacer-
bations in this way allowed documentation of the number 
and severity of any COPD-related exacerbations during 
the study.
Patients were instructed to contact the clinical team 
every time they felt a worsening of their COPD. On 
signaling of a “patient-defined exacerbation”, patients 
were contacted by the clinical team to confirm or other-
wise the presence of a COPD-related exacerbation (“clin-
ician-defined exacerbation”). Patients were also provided 
with advice on taking rescue treatment (steroids and/or 
antibiotics). Further clinician-led intervention was initiated 
if patients did not respond to the rescue medication and the 
monitored health data indicated delayed recovery.
COPDPredictTM Exacerbation Algorithm
The study design was used for the algorithm decision tree 
and split sequentially based on routine daily Wellbeing 
Score entries and weekly spirometry. Derogation to this 
testing frequency was based on the alerting thresholds for 
both Wellbeing Score and FEV1 which could prompt 
further testing of FEV1 and/or blood CRP test. One key 
feature of the exacerbation prediction model was the 
2-week learning phase in the first fortnight when baseline 
data entries required daily Wellbeing Scores, FEV1 every 
3rd day and blood CRP levels at Day 1 and 14. This set the 
personalised critical stable baseline for each parameter. 
The percentage differences between the 50th percentile 
prodromal value and baseline value and absolute value 
changes were used to set alert thresholds for changes in 
disease state (eg, stable, prodromal), with receiver operat-
ing characteristics (ROC) curves used to define stable to 
exacerbation alert thresholds. Alerting thresholds were 
thus defined separately for each parameter and universally 
set for all patients. Automatic reminders were sent to 
patients if the wellbeing self-assessment was not com-
pleted within 24 hours. However, patients could submit 
more than one self-assessment daily if they felt their health 
had changed during the course of a day; with a Wellbeing 
Score calculated for each generated self-assessment, thus 
providing real-time information on how the patient was 
feeling (and any change in circumstance).
Statistical Analysis
Statistical analysis was performed using IBM SPSS 
Statistics Version 24 (IBM, USA). Parametric data were 
expressed as mean ± standard deviation, and non- 
parametric as median, interquartile range (IQR).
All “clinician-defined” exacerbations were cross- 
compared to the “algorithm-defined” exacerbation notifi-
cations to allow for cross-analysis to determine the accu-
racy, sensitivity, specificity, and the algorithm’s predictive 
timing for exacerbation detection. All data was cross- 
referenced with the registered clinical history of each 
patient to ensure accuracy. The prodrome of an 
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exacerbation was defined as 14 days prior to the onset of 
a clinician-defined exacerbation. By analyzing a 14-day 
window prior to the onset of a clinician-defined exacerba-
tion, it was possible to explore whether the notifications 
generated by the COPDPredict™ model provided an early 
warning to an imminent exacerbation. Sensitivity, specifi-
city, positive, negative predictive values, positive, negative 
likelihood ratios, and accuracy were calculated with con-
fidence intervals (CI) using “exact” Clopper–Pearson, Log 
method and standard logit tests.
For non-parametric data, between-group comparison 
was performed using Mann–Whitney U-test, and 
Kruskal–Wallis one-way analysis of variance (ANOVA). 
For parametric data, between-group comparison was per-
formed using a paired t-test. A p-value of less than 0.05 
was considered statistically significant.
Results
Ninety patients with COPD (Table 1: 45 males and 45 
females; age range 48 to 91 years; FEV1 range 15% to 
86% predicted) completed the 6-month study; no adverse 
events or deaths were reported. There was 98% patient 
compliance with completing the daily wellbeing self- 
assessments, supported by timed automatic prompt notifi-
cations via the App. There were 19 separate instances 
when patients submitted more than one daily wellbeing 
assessment; in all these instances, patients had felt 
a significant worsening in their breathing and/or cough 
since recording their assessment earlier in the same day. 
Some patients (12 out of 90) used the free text section at 
the end of the self-assessment to explain their wellbeing in 
their own words: Comments included “Much better today 
on treatment”; “Feeling generally off”.
Exacerbations
During the study period, 112 clinician-defined exacerba-
tions (108 mild/moderate; 4 severe) were evidenced in 80 
patients; 10 patients did not experience a significant acute 
episode and self-managed minor symptoms with adjust-
ments to usual inhaler therapy in accordance with their 
action plans. Of the 80 patients who experienced exacer-
bations (Table 2), 52 had just one exacerbation, whilst the 
remaining 28 patients experienced more than 1 acute epi-
sode (2.2 ± 0.4 episodes) (Table 3).
Sixty-two of the 80 exacerbating patients managed 
their exacerbation events at home using the provided “res-
cue pack” of oral prednisolone ± antibiotics as directed by 
the clinicians and action plan which followed best clinical 
practice in line with national/international guidelines for 
COPD exacerbation management.18,26 In this study, anti-
biotics were considered on an individual patient basis; 
generally, all patients showing increased sputum purulence 
and/or high CRP levels were directed to take antibiotics in 
addition to prednisolone. Fourteen participants did not 
improve on standard treatment alone and required esca-
lated home treatment involving nebulised salbutamol 
2.5mg ± ipratropium bromide 500µg therapy for 7 days 
using the AKITA® Jet Inhalation System (Vectura®, UK). 
All 14 cases were identified correctly by COPDPredict™ 
with “high risk” notification alerts displayed against the 
respective patients on the decision support dashboard.
Hospitalisations
Only 4 of the total 80 exacerbators attended the emergency 
department, after having already started on their appropri-
ate rescue medication at home: 2 attendees required chest 
radiograph and ECG tests to exclude pneumonia and 
a cardiac event, respectively, and were discharged home 
upon exclusion; the other 2 attendees were admitted for 
stabilisation of their known respiratory failure and stayed 
for less than 72 hours. All 4 patients resumed with 
COPDPredict™ following discharge from emergency 
room/hospital.
Compared to the total number of in-patient hospitalisa-
tions for all patients in the 6 months pre-COPDPredict™, 
hospitalisations during the 6-month period with 
COPDPredict™ were reduced by 98% (90 vs 2, p<0.001). 
All patients were followed up for 30 days following treat-
ment for an index exacerbation; none of the patients who 
were treated at home or who had attended the emergency 
room/been hospitalised needed admission or readmission.
Validity of the COPDPredict™ 
Exacerbation Prediction Algorithm
Collected data from 3257 time-points across the study 
period allowed validation of the prediction algorithms. 
Cross-tabulation analysis between “algorithm-defined” 
and clinician-defined exacerbations demonstrated that 
COPDPredict™ identified COPD-related exacerbations at 
7, 3 days (median, IQR) prior to clinician-defined epi-
sodes, sending appropriate alerts to patients and clinicians.
Figure 3 demonstrates the breakdown for the entire 
exacerbation prediction algorithm. COPDPredict™ 
advised on the prodromal status of an impending exacer-
bation in 285 out of 291 timepoints demonstrating 
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a sensitivity of 97.9% (95% CI: 95.7–99.2), specificity of 
84.0% (95% CI: 82.6–85.3), with a positive predictive 
value of 38.4% (95% CI: 36.4–40.4) and a negative 
predictive value of 99.8% (95% CI: 99.5–99.9). The 
accuracy for the prediction of an exacerbation was 
85.3% (95% CI: 84.0–86.5); a positive likelihood ratio 
of 6.12 (95% CI: 5.61–6.66) and a negative likelihood 
ratio of 0.02 (95% CI: 0.01–0.05). Taken together, the 
high sensitivity and specificity coupled with the high 
negative predictive value means that COPDPredict™ 
will not miss an imminent exacerbation or fail to alert 
the patient and healthcare professional of that pending 
exacerbation.
In contrast, analysis of algorithm outputs utilising only 
Wellbeing Score and FEV1 demonstrated that the prediction 
algorithm advised on imminent exacerbations in only 224 
out of 291 timepoints. This reflected a lower sensitivity of 
77.0% (95% CI: 71.7–81.7), a specificity of 65.0% (95% CI: 
63.2–66.8), and positive and negative predictive value of 
18.3% (95% CI: 17.1–19.5) and 96.5% (95% CI: 95.7– 
97.2), respectively. The accuracy for exacerbation prediction 
was 66.1% (95% CI: 64.4–67.8) with a positive likelihood 
ratio of 2.2 (95% CI: 2.03–2.38) and negative likelihood 
ratio of 0.35 (95% CI: 0.29–0.44). These results support our 
approach of combining patient-reported outcomes with bio- 
physiological metrics for optimal precision of the exacerba-
tion prediction algorithms.
Discussion
In this study, we demonstrated that COPDPredict™ can 
enable safe, reliable continuous self-monitoring and pro-
vide early detection of exacerbations in a high-risk COPD 
population. We have presented a unique bio-clinical profil-
ing approach for the acquisition of patient-specific critical 
datasets over time, allowing changes in health status (eg, 
stable to prodrome to exacerbation to recovery) to be 
determined on a personalised basis and for exacerbation 
prediction and severity stratification to be clinically mean-
ingful. Combining patient-reported outcomes with objec-
tive bio-physiological parameters contributes to the 
robustness of COPDPredict™’s prediction algorithms, 
reflected in high sensitivity (98%) and specificity (84%) 
plus high negative predictive value (99.8%). Accurate 
exacerbation prediction will likely become a benchmark 
for home monitoring technologies as the demand for pre-
cise personalised care increases: “Developing predictive 
Table 1 Patient Characteristics at Enrolment (n = 90)
Demographics (n = 90) I (n = 8) II (n = 37) III (n = 33) IV (n = 12)
Age a(years) 69 ± 8 70 ± 6 66 ± 8 71 ± 8 68 ± 7
Gender, Male (Female) 45 (45) 2 (5) 13 (11) 10 (9) 2 (3)
Duration of COPD a(years) 9 ± 7 11 ± 10 7 ± 4 9 ± 8 7 ± 3
*Stable FEV1 
a(% predicted) 50 ± 20 86 ± 7 60 ± 9 41 ± 4 26 ± 8
BMI, a(kg/m2) 27 ± 6 29 ± 5 28 ± 6 25 ± 5 26 ± 5
MRC Score b(n) 3.0, 2.0 3.0, 0.5 3.0, 1.5 3.0, 1.0 3.0, 2.8
Exacerbations in the previous 1year a(n) 4.0 ± 2.2 4.9 ± 3.3 4.3 ± 1.1 4.2 ± 3.6 4.2 ± 1.3
Hospitalisations for AECOPD in the previous 6 months a(n) 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0
Co-morbidities
None 20 3 7 6 4
Cardiovascular 38 3 21 13 1
Type 2 Diabetes Mellitus 14 2 6 3 3
Other 24 3 10 9 2
COPD Medications
β2-Agonists, Short Acting, (Long Acting) 88, (79) 8, (6) 37, (37) 33, (33) 10, (3)
Anticholinergic, Short Acting, (Long Acting) 7, (67) 0, (5) 2, (27) 3, (26) 2, (9)
Inhaled Steroid 78 6 29 31 12
Oral Theophylline 17 1 7 5 4
Notes: Data presented as aMean ± standard deviation and bMedian, inter-quartile range. Roman numerals represent GOLD categorization of airflow limitation severity: I = 
mild, II = moderate, III = severe, IV = very severe. *Statistically significant difference between FEV1 across the four (I, II, III, IV) groups (p<0.001). 
Abbreviations: COPD, chronic obstructive pulmonary disease; n, number; FEV1, forced expiratory volume in 1 second; BMI, body mass index; kg, kilogram; m, meter; 
MRC, medical research council; AECOPD, acute exacerbation of chronic obstructive pulmonary disease.
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Bronchodilators+ Steroids + 
Antibiotics (n = 14)
Exacerbators Steroids + 
Antibiotics Attended 
Hospital (n = 4)
Age, ayears 69 ± 8 68 ± 16 69 ± 8 69 ± 8
Gender, Male (Female) 5 (5) 31, (31) 5, (9) 4, (0)
Duration of COPD, ayears 8 ± 7 8 ± 6 14 ± 8 14 ± 11
MRC Score, bn 3.0, 0.75 3.0, 2.0 3.0, 2.0 4.0, 0.5
Exacerbations in previous 
1 year, an
2.5 ± 1.0 4.3 ± 2.4 3.9 ± 2.1 3.8 ± 2.4
Exacerbations in the study, an 0 1.4 ± 0.6 1.7 ± 0.8 2.0 ± 0.0
Smoking Status, Current, (Ex) 2, (8) 6, (56) 2, (12) 3, (1)
Co-morbidities
None 2 16 2 0
Cardiovascular 4 24 8 2
Type 2 Diabetes Mellitus 0 11 2 1
Other 6 5 9 4
COPD Medications
β2 Agonists, Short Acting, 
(Long Acting)
10, (7) 60, (55) 14, (13) 4, (4)
Anticholinergic, Short Acting, 
(Long Acting)
2, (7) 4, (45) 0, (12) 1, (3)
Inhaled Steroid 5 56 13 4
Oral Theophylline 1 14 0 2
Assessment Data
Wellbeing Score, bn – Stable 14, (6–19) 16, (7–24) 13, (8–28) 19, (17–21)
Wellbeing Score, bn – 
Exacerbation
n/a 20, (10–31) 23, (15–31) 25, (20–26)
FEV1, 
a(% predicted) – Stable 54 ± 30 49 ± 19 42 ± 16 47 ± 14
FEV1, 
a(% predicted) – 
Exacerbation
n/a 46 ± 19 38 ± 15 30 ± 6
Blood CRP b(mg/L) – Stable 3.0, (1.8–10.0) 3.6, (1.5–30.0) 4.0, (0.1–10.6) 2.2, (1.0–21.0)
Blood CRP b(mg/L) – 
Exacerbation
n/a 5.4, (0.2–55.9) 13.5, (1.7–64.0) 12.4, (2.0–21.0)
Note: Data presented as aMean ± standard deviation and bMedian, interquartile range. 
Abbreviations: COPD, chronic obstructive pulmonary disease; n, number; FEV1, forced expiratory volume in 1 second; BMI, body mass index; kg, kilogram; m, meter; 
MRC, medical research council; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; CRP, c-reactive protein.
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algorithms with clinically useful levels of sensitivity and 
specificity is a priority for future development of telemo-
nitoring of COPD” as non-intuitive systems can produce 
unnecessary alerts causing stress and anxiety in patients.32
Exacerbations and consequent hospitalisations are out-
comes that COPD patients’ rate as most important to 
them.33 Current guidelines18,26,34 recommend an exacerba-
tion action plan based on patient-reported symptoms for all 
COPD patients. However, our results suggest that action 
plans supported by digital technologies with embedded 
exacerbation prediction would improve exacerbation 
management and patient outcomes. Indeed, many patients 
are unable to differentiate between “usual” variations in 
COPD health and discrete increased symptoms, and delay 
or fail to respond to impending exacerbations 
adequately.13,14,35 It follows that at a clinical service 
level, COPDPredict™ could enhance home-monitoring 
and optimize self-management for patients, whilst allow-
ing clinicians to review their patients’ progress and initiate 
tailored intervention and support promptly. Our study 
demonstrated that COPDPredict™ identified COPD- 
related exacerbations at 7, 3 days (median, IQR) prior to 
clinician-defined episodes, sending appropriate alerts to 
both patients and clinicians. Specifically, the 
COPDPredict™ alerts provided sufficient time for instigat-
ing appropriate treatment at home in most patients, avoid-
ing unnecessary hospital admissions and use of stretched 
hospital-based resources. Whilst outside this study’s objec-
tives, a preliminary economic impact evaluation suggests 
that COPDPredict™ could alleviate the burden on 
stretched hospital-based resources and reduce current 
costs associated with exacerbation-related hospitalisations 
and in-patient bed days.
Remote monitoring interventions have been reported as 
presenting some usability issues in the real-world.36 Our 
study showed a 98% compliance for patient completion of 
daily wellbeing self-assessments; similarly, patients com-
plied with performing spirometry and reacted responsibly to 
notifications. This sustained compliance and positive inter-
action with the App over the 6 months are likely due to 
a number of factors: (1) Design and development of 
COPDPredict™ was driven from a patient’s perspective; 
patients were intentionally involved throughout the produc-
tion phases as “experts by experience”;37 (2) Patients were 
reminded to submit assessments via automatic prompts; (3) 
Patients were reassured by the interactive functionality of 
the system: a) their health status could be reviewed by the 
clinical team in real-time and at any time; b) any changes in 
health prompted automatic alerts to them and their clini-
cians; and c) they could communicate directly with clini-
cians using the App’s messaging facility; patients found this 
to be most useful for instant clarifications on treatments and 
health-related queries. Indeed, multicomponent interven-
tions with action plans for exacerbation management are 
effective in reducing admissions only when they offer itera-
tive feedback to patients.38
Measurement of CRP was a vital input for the robust-
ness of the exacerbation prediction algorithm, influencing 
its sensitivity and specificity. C-reactive protein testing is 








Age, ayears 69 ± 8 68 ± 9
Gender, Male (Female) 27 (25) 13 (15)
Duration of COPD, ayears 10 ± 7 8 ± 6
*FEV1, a(% predicted) 48 ± 19 43 ± 15
MRC Score, bn 3.0, 1.0 3.0, 1.5
Exacerbations in the previous 
1 year, an
4.0 ± 2.0 4.8 ± 2.8




Type 2 Diabetes Mellitus 6 8
Other 6 12
Total Co-morbidities an 1.2 ± 1.0 1.5 ± 0.9
COPD Medications
β2 Agonists, Short Acting, 
(Long Acting)
52, (46) 26, (26)
Anticholinergic, Short Acting, 
(Long Acting)
4, (36) 1, (24)
Inhaled Steroid 46 27
Oral Theophylline 10 6
Notes: Data presented as aMean ± standard deviation and bMedian, interquartile 
range. *Statistically significant difference (p<0.001). 
Abbreviations: COPD, chronic obstructive pulmonary disease; n, number; FEV1, 
forced expiratory volume in 1 second; BMI, body mass index; kg, kilogram; m, 
meter; MRC, medical research council; AECOPD, acute exacerbation of chronic 
obstructive pulmonary disease.
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practically achievable within the home and community 
(GP or pharmacy-based), avoiding the need for patients 
to attend hospital centres for blood tests. Furthermore, 
point-of-care CRP testing can reduce unnecessary antibio-
tic prescribing for respiratory tract infections in 
exacerbations.39,40
Strengths and Limitations
We are aware of published work using symptoms and 
physiological parameters for COPD exacerbation 
prediction,22,23,41,42 but to the best of our knowledge 
COPDPredict™ is the first validated digital application 
offering an exacerbation prediction algorithm driven by 
a combination of patient-report outcomes (wellbeing scores) 
and reliable bio-physiological inputs (FEV1 and CRP 
levels). A key feature of the algorithm decision tree is the 
creation of an individual’s stable baseline which accommo-
dates for intra- and inter-person variability in an extremely 
heterogeneous clinical condition. This improves on predic-
tion tools that rely on fixed thresholds or manual tuning by 
healthcare professionals.21 Our approach also allows for 
each patient’s “stable state” baseline to be reset as appro-
priate throughout the possible changing dynamics of their 
chronic condition. This aspect of COPDPredict™ has not 
been fully tested within the time limits of the current study 
and will require further evaluation.
Figure 3 Sensitivity and specificity of the exacerbation prediction algorithm. 
Notes: AECOPD: acute exacerbation of chronic obstructive pulmonary disease, *failure to enter a wellbeing score or perform spirometry; **AECOPD during 2-week 
baseline phase. The sensitivity and specificity percentages are highlighted in bold. This image is the property of the author.
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In-depth analyses of the prediction alert data show that 
COPDPredict™ could identify those patients likely to re- 
exacerbate within 30 days of an index exacerbation. 
Preliminary findings indicate that “re-exacerbating” 
patients had higher wellbeing scores and CRP levels and 
lowest FEV1 at the time of exacerbation. This observation 
requires further evaluation over a longer study period and 
in a larger patient cohort; this is currently in progress 
(NCT04136418). If confirmed, COPDPredict™ would 
additionally predict those patients likely to re-exacerbate 
and/or be readmitted, prompting higher levels of interven-
tion and/or longer treatment periods.
We have selectively biased towards a COPD frequent 
exacerbator cohort as our objective was to validate 
COPDPredict™ as an effective tool for predicting exacer-
bations. In practice, these patients are frequently hospita-
lised and have the poorest outcomes. However, 
COPDPredict™ is not precluded from being used in all 
COPD patients to enhance their self-management and pre-
vent them from becoming frequent exacerbators.
Conclusion
We have demonstrated COPDPredict™ is safe and can 
provide a model of care based around prevention, combing 
remote monitoring and patient-specific exacerbation pre-
diction. The prediction algorithm reliably and promptly 
informs both patients and clinicians on acute events, pro-
viding an opportunity to intervene and reducing unneces-
sary hospitalisation. We anticipate that as COPDPredict™ 
accumulates individual-specific datasets over time, 
enabled machine learning will identify patterns in exacer-
bation etiology and treatment responses to improve pre-
diction of exacerbations and individual outcomes.
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